Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) shares were up 1.1% during mid-day trading on Friday . The stock traded as high as $10.40 and last traded at $9.78. Approximately 220,419 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,377,421 shares. The stock had previously closed at $9.67.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock.
Read Our Latest Stock Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Trading Up 0.8 %
Hedge Funds Weigh In On Tonix Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of TNXP. Geode Capital Management LLC grew its position in Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares during the period. Jane Street Group LLC grew its position in shares of Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares during the period. Point72 Asset Management L.P. bought a new stake in Tonix Pharmaceuticals during the fourth quarter valued at about $526,000. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $162,000. Finally, PFG Investments LLC bought a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $72,000. Institutional investors own 82.26% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
See Also
- Five stocks we like better than Tonix Pharmaceuticals
- Using the MarketBeat Dividend Tax Calculator
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Overbought Stocks Explained: Should You Trade Them?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Investing in Commodities: What Are They? How to Invest in Them
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.